(Q34553464)

3 August 2017

title

Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro (English)

1 reference

3 August 2017

main subject

Staphylococcus aureus

1 reference

1 reference

1 reference

1 reference

Marcia S Osburne

1

1 reference

3 August 2017

Christopher K Murphy

series ordinal

2

1 reference

3 August 2017

David M Rothstein

series ordinal

3

1 reference

3 August 2017

publication date

1 May 2006

1 reference

The Journal of Antibiotics

3 August 2017

published in

1 reference

3 August 2017

volume

59

1 reference

3 August 2017

issue

5

1 reference

3 August 2017

page(s)

303-308

1 reference

Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

Comparison of Techniques for Measurement of in Vitro Antibiotic Synergism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

Method of reliable determination of minimal lethal antibiotic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

Development potential of rifalazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In vitro time-kill activities of rifalazil, alone and in combination with vancomycin, against logarithmic and stationary cultures of Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In vitro activity of mupirocin and amoxicillin-clavulanate alone and in combination against staphylococci including those resistant to methicillin

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.43

7 January 2021

Identifiers

DOI

10.1038/JA.2006.43

1 reference

Dimensions Publication ID

3 August 2017

1026450242

0 references

1 reference